Status:
COMPLETED
Predictive Role of KLK10 and Other Neuroinflammatory Molecules on Clinical Outcomes of AIS
Lead Sponsor:
Ruijin Hospital
Conditions:
Ischemic Stroke
Eligibility:
All Genders
Brief Summary
This study aims to investigate the dynamic changes and differential expression characteristics of neuroinflammatory molecules such as kallikrein-related peptidase 10 (KLK10), soluble triggering recept...
Detailed Description
1. Informed Consent and Recruitment: Participants will be recruited based on inclusion and exclusion criteria. 2. divided two groups: the case group(ischemic stroke group) and the control group(health...
Eligibility Criteria
Inclusion
- for AIS patients:
- Selection of 182 patients with first-ever acute ischemic stroke (AIS) who are hospitalized at our hospital, aged ≥18 years, with no restriction on gender;
- Patients must be admitted within 24 hours of the onset of AIS;
- Diagnosis must be confirmed by cranial magnetic resonance imaging (MRI) or computed tomography (CT);
- All enrolled patients must provide written informed consent.
- for healthy controls:
- Age and gender-matched;
- No organic diseases;
- Written informed consent must be signed
Exclusion
- Intracranial hemorrhage;
- Pregnancy;
- Stroke with unknown onset time;
- Malignant tumors;
- Hematologic disorders;
- Severe liver or kidney dysfunction;
- Recent myocardial infarction (less than 3 months);
- Ongoing anti-inflammatory drug treatment.
Key Trial Info
Start Date :
August 12 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2025
Estimated Enrollment :
273 Patients enrolled
Trial Details
Trial ID
NCT06549972
Start Date
August 12 2024
End Date
June 30 2025
Last Update
July 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025